Table 2.

Comparison of two US FDA approved CAR-T products for B cell malignancies

Medicine	Signaling motifs	Dosage	Indication
YESCARTA Axicabtagene ciloleucel (Yescarta)	CD28 and CD3ζ	2 × 106 CAR-positive viable T cells per kg body weight, with a maximum of 2 × 108 CAR-positive viable T cells.	• Adult patients with relapsed or refractory large B cell lymphoma after two or more lines of systemic therapy, including diffuse large B cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B cell lymphoma, high grade B cell lymphoma, and DLBCL arising from follicular lymphoma.
KYMRIAH™ Tisagenlecleucel (Kymriah)	CD137 (4-1BB) and CD3ζ	Pediatric and young adult B cell ALL (up to 25 years of age): • For patients 50 kg or less, administer 0.2 to 5.0 × 106 CAR-positive viable T cells per kg body weight intravenously. • For patients above 50 kg, administer 0.1 to 2.5 × 108 total CAR-positive viable T cells (non-weight based) intravenously. Adult relapsed or refractory diffuse large B cell lymphoma: • Administer 0.6 to 6.0 × 108 CAR-positive viable T cells intravenously.	• Patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. • Adult patients with relapsed or refractory (r/r) large B cell lymphoma after two or more lines of systemic therapy including diffuse large B cell lymphoma (DLBCL) not otherwise specified, high grade B cell lymphoma and DLBCL arising from follicular lymphoma, excluding primary central nervous system lymphoma.